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Abstract
Neurologists managing women with Multiple Sclerosis (MS) need information about the safety of disease modifying drugs 
(DMDs) during pregnancy. However, this knowledge is limited. The present study aims to summarize previous studies by 
performing a systematic review and meta-analyses. The terms “multiple sclerosis” combined with DMDs of interest and a 
broad profile for pregnancy terms were used to search Embase and Medline databases to identify relevant studies published 
from January 2000 to July 2019.1260 studies were identified and ten studies met our inclusion criteria. Pooled risk ratios 
(RR) of pregnancy and birth outcomes in pregnancies exposed to DMDs compared to those not exposed were calculated 
using a random effects model. For spontaneous abortion RR = 1.14, 95% CI 0.99–1.32, for preterm births RR = 0.93, 95% 
CI 0.72–1.21 and for major congenital malformations RR = 0.86, 95% CI 0.47–1.56. The most common major congenital 
malformations reported in MS patients exposed to MS drugs were atrial septal defect (ASD) (N = 4), polydactyly (N = 4) 
and club foot (N = 3), which are among the most prevalent birth defects observed in the general population. In conclusion, 
interferons, glatiramer acetate or natalizumab, do not appear to increase the risk for spontaneous abortions, pre-term birth 
or major congenital malformations. There were very few patients included that were exposed to fingolimod, azathioprine 
and rituximab; therefore, these results cannot be generalized across drugs. Future studies including internal comparators are 
needed to enable treating physicians and their patients to decide on the best treatment options.
Keywords Multiple sclerosis · Pregnancy · Congenital malformations · Preterm · Spontaneous abortions
Introduction
Multiple sclerosis (MS) is a chronic neurological disease that 
affects more women than men, with a female-to-male ratio 
of 2:1 [1]. MS is generally diagnosed during childbearing 
age [1]. Symptoms associated with MS may occur in isolated 
attacks or build up over time. Between attacks, symptoms 
may disappear completely; however, permanent neurologi-
cal problems often remain. Hence, the initiation of early-
treatment with disease modifying drugs (DMDs) is recom-
mended [2].
Neurologists managing women with MS who wish to 
conceive need to use a benefit-risk approach and provide 
adequate advice to their patients. Physicians also need to 
be prepared in case women taking DMDs become pregnant 
given that many pregnancies occur unplanned, and there-
fore, women with MS may inadvertently take DMDs whilst 
pregnant. It is essential to balance the risk of DMDs during 
pregnancy to the fetus as compared to the risk of inadequate 
treatment in the mother. During pregnancy lack of treatment 
may lead to the development of irreversible disability, since 
stopping an efficacious drug may induce a relapse [3].
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Despite previous systematic reviews and studies [4–6], 
knowledge about the consequences of treatment with DMDs 
during pregnancy is limited. Based on animal studies and 
as a result of limited data in humans, the Food and Drug 
Administration (FDA) assigned category C to the use of 
most of the DMDs during pregnancy. This category states: 
“Risk not ruled out: Animal reproduction studies have shown 
an adverse effect on the fetus and there are no adequate and 
well-controlled studies in humans, but potential benefits may 
warrant use of the drug in pregnant women despite poten-
tial risks”. The use of pregnancy risk categories presented 
a challenge for many health care providers, since it did not 
include enough detailed information related to the safety and 
efficacy of medications in pregnancy and lactation to assist 
them in making more evidence-based decisions. As a result, 
in December 2014 FDA introduced the Pregnancy and Lac-
tation Labeling Rule (PLLR) which removed the pregnancy 
letter categories. In place of these pregnancy categories, the 
PLLR requires narrative explanations of risk and supporting 
data [7]. The EMA provides a decision scheme that helps 
determine whether or not a contraindication during preg-
nancy should be settled in the labelling [8]. This guideline 
considers all non-clinical and clinical data to make an inte-
grated approach in the risk assessment. In recent years, the 
landscape of MS treatment has changed, with an increasing 
number of treatment options that have a long-lasting disease 
modifying effect. Due to the longer half-lives, there is poten-
tially a longer impact during pregnancy. Studies in pregnant 
women with newer DMDs are scarce.
The aim of this meta-analysis is to evaluate pregnancy 
outcomes in women with MS treated with DMDs. The 
results will add to the existing evidence for women with 
MS considering pregnancy and for neurologists deciding on 
treatment around pregnancy and counselling women with 
unplanned pregnancies. This study will also help understand 
what evidence is lacking in order to provide guidance on 
what to consider when performing future studies that evalu-
ate clerosis MS treatment during pregnancy.
Methods
Search strategy
The PRISMA 2009 guidelines were followed throughout 
the study [9]. Searches in Embase and Medline were con-
ducted May–August 2019 to identify relevant publications 
from the period January 2000 to August 2019. The term 
multiple sclerosis was combined together with DMDs of 
interest with a broad profile for pregnancy terms. DMDs of 
interest were: interferon β-1a, interferon β-1b, PEG inter-
feron β-1a, alemtuzumab, cladribine, dimethyl fumarate, 
fingolimod, glatiramer acetate, laquinimod, natalizumab, 
teriflunomide, methotrexate, cyclophosphamide, mycophe-
nolate mofetil, azathioprine, rituximab, mitoxantrone teriflu-
nomide, laquinimod, natalizumab, ofatumumab, rituximab, 
ocrelizumab, disease modifying, DMD, DMDs B-cell ther-
apy. The pregnancy terms used were: pregnancy, gravidity, 
prenatal, maternal, gestation, pregnancies, pregnant, preg-
nanc*, fetal, foetal and congenital. The search was restricted 
to publications in English. The search was performed using 
the databases’ controlled vocabulary as well as free-text 
terms including various spellings and synonyms. Duplicates 
were removed.
Eligibility criteria
Titles and abstracts were screened to identify peer-reviewed 
studies which measured the effects of MS drugs on preg-
nancy. Only studies in which the exposure occurred in utero 
and compared patients exposed to an MS drug against MS 
patients without treatment or against the general population 
were included. Studies which mixed unexposed and exposed 
in the same group were excluded (e.g., MS patients with and 
without treatment). However, if the studies included patients 
taking different DMDs and compared them with one control 
group they were included as a general DMD group. Inter-
ventional studies (e.g., randomized clinical trials) as well as 
non-interventional studies (e.g., cohort, case–control, and 
registries) were included.
To avoid bias, studies where the pregnancy outcome was 
known when the patient entered the study (e.g., retrospective 
cases) were excluded. Therefore, the pregnancy outcomes 
were assessed independently of the knowledge regarding 
pregnancy exposure.
Both primary data collection (e.g., registry studies) as 
well as studies that included secondary sources (e.g., claims 
databases) of data were considered. Abstract, reviews, case 
reports, case series and spontaneous reports were excluded. 
There was no exclusion based on the pregnancy outcomes, 
all outcomes available were included.
Data extraction
Two reviewers (MT, MS) independently reviewed the search 
results for inclusion narrowing potential studies successively 
in three stages: by title, by abstract, and by full manuscript. 
Disagreements regarding eligibility were discussed amongst 
all authors. The quality of eligible studies was independently 
assessed by SLL and CW using the New Castle Ottawa scale 
(NOS) [9]. Studies with NOS scores greater than six points 
were considered to be of high quality. Data from all selected 
articles were extracted by two authors (MT and SLL) and a 
quality control, by detecting inconsistencies, was performed 
by another author (CW).
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Statistical analysis
The primary analyses consisted of calculating pooled risk 
ratios (RR) of pregnancy and birth outcomes (spontaneous 
abortions, pre-term birth and congenital malformations) 
in pregnancies exposed to multiple sclerosis drugs com-
pared to those not exposed. All MS drugs were studied 
together overall, and when possible stratified by drug class 
[interferons, natalizumab and glatiramer acetate (GA)] to 
study each individual DMD separately. The pooled RR of 
all meta-analyses were calculated using a random effects 
model. The relative weight for each study is calculated as 
the inverse of the sum of the individual study variance plus 
the between study variance. The weight for each study is 
then the relative weight expressed as a proportion of all the 
relative weights of the studies in the analysis. Therefore, 
the weight for any study will vary according not only to 
the number of events occurring in that study and the size 
of the study, but also to the number of events and size in 
other studies and also how consistent the study effect is 
between the studies. The data were analyzed using STATA 
Version 15.
The secondary analyses consisted of calculating the 
pooled prevalence rate of the pregnancy outcomes which 
had two or more published studies in untreated as well as 
treated MS patients. MetaXL software was used to esti-
mate the pooled prevalence which uses a double arcsine 
transformation [10].
For all outcomes, except congenital malformations, 
“all pregnancies” (live birth, spontaneous abortion, or 
termination of pregnancy) were used as the denominator. 
In relation to major congenital malformations, all stud-
ies used “live births”; therefore, live births were used as 
the denominator. Heterogeneity was assessed using the 
I2 statistics. Values of 25%, 50% and 75% for I2 repre-
sented low, medium and high heterogeneity, respectively 
[11]. Publication bias was considered using funnel plots 
and assessed with Harbord’s modified test for small-study 
effects.
Results
Study selection and characteristics
The study search and selection processes are described in 
detail in Fig. 1. The initial search yielded 1260 publications. 
After removing duplicates 891 publications were identified. 
The titles and abstracts were then screened; 832 studies were 
out of scope and 59 studies were assessed in full. Only ten 
studies met our inclusion criteria. These ten studies were 
considered to be of high quality based on the NCO scale 
(NOS) and were included in the meta-analyses.
Studies included
Table 1 provides characteristics of the included studies. The 
studies were from Germany (N = 4), Canada (N = 2), Spain, 
Italy, US and Worldwide. The studies from Germany came 
from the same cohort; however, the data were not duplicated 
as the studies selected included different dates or medica-
tions. All of the studies were observational studies.
The drugs that were studied the most were interferon, 
glatiramer acetate, natalizumab. There were very few 
patients included that were treated with fingolimod, azathi-
oprine or rituximab, MacDonald et al. [12] did not stratify 
their analyses by type of drug and only conducted their anal-
yses as overall. Therefore, it was not possible to include their 
data in the drug-specific analyses. Five of the studies only 
included patients exposed to DMD during the first trimester 
[5, 13–16]. None of the studies stratified by trimester of 
exposure. All of the studies, except one, included as control 
Fig. 1  Flowchart depicting 
the study selection and record 
screening process
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patients with multiple sclerosis that were not exposed to dis-
ease modifying drugs. The comparison group in the study by 
Ebrahimi et al. [16] included a mixture of multiple sclero-
sis patients treated with other DMDs than natalizumab and 
untreated MS patients. Therefore, the data from this study 
were only included in the pooled estimated prevalence but 
not in the meta-analysis of risk ratios.
The birth outcomes in which there were enough stud-
ies to conduct a meta-analysis were spontaneous abortions, 
pre-term births and congenital malformations. All studies 
defined spontaneous abortions as fetal loss before week 22nd 
of pregnancy. Pre-term birth was defined in all studies as 
birth before week 37th of pregnancy. All of the studies did 
not give a definition for adjudication of the malformations 
nor stated what system they used to define them, they just 
referred to them as “major malformations”, “major struc-
tural malformations” or “major birth defects”. There was no 
standardization in the definition or wording used. All of the 
studies, except one, specified that they were major malfor-
mations. The study that only referred to them as “congenital 
malformations” reported that there were none present [13].
Meta‑analysis of risk ratios
Figures 2, 3 and 4 present meta-analysis for spontaneous 
abortions (from eight studies), pre-term births (from seven 
studies) and major congenital malformations (from eight 
studies) both overall for all MS drugs as well as strati-
fied by drug class. The RR for spontaneous abortion was 
RR = 1.14, 95% CI 0.99–1.320, for preterm births RR = 0.93, 
95% CI 0.72–1.21 and for major congenital malformations 
RR = 0.86, 95% CI 0.47–1.56 when compared to MS without 
treatment. The evidence for heterogeneity was low for spon-
taneous abortions (I2 = 0%) and major congenital malforma-
tions (I2 = 26.1) and medium for preterm birth (I2 = 46.0%). 
There was no evidence of publication bias.
Pooled prevalence
Table 2 presents the pooled estimated prevalence for spon-
taneous abortions, premature births and major congenital 
malformations in untreated as well as treated MS patients. 
The prevalence for untreated MS patients was: spontane-
ous abortions 10.9% (95% CI 5.2–18.3) premature birth 
12.1% (7.4–17.7) and major congenital malformations 
4.2% (2.7–6.1). The prevalence for treated MS patients 
was: spontaneous abortions 11.6% (7.4–16.7), premature 
birth 12.12% (9.0–15.6) and major congenital malformations 
3.0% (1.8–4.4). The I2 value was extremely high for each 
pooled outcome, indicating the extremely wide variation in 
reported prevalences for these outcomes. Ta
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Major malformations
The most common major congenital malformations in MS 
patients exposed to MS drugs were atrial septal defect 
(ASD) (N = 4), polydactyly (N = 4) and club foot (N = 3). 
Each case of atrial septal defect was present in patients 
exposed to different drugs (natalizumab, β-interferon, GA 
and Mitoxantrone). For the unexposed MS patients most 
of the studies did not specify what major malformation 
was present (Table 3). There were only two studies that 
reported one dysmelia of the tibia and fibula and three 
ASD [13, 14].
Discussion
The objective of this meta-analysis was to assess if patients 
treated for MS had an increased risk of adverse pregnancy 
outcomes compared to MS untreated patients. The outcomes 
that were possible to study were spontaneous abortions, 
Fig. 2  a Meta-analysis sponta-
neous abortions: treated MS vs 
untreated MS. b Meta-analysis 
spontaneous abortions: treated 
MS vs untreated MS stratified 
by drug
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pre-term live births and major congenital malformations in 
live births. The results showed that treatment in general did 
not appear to be associated with these adverse pregnancy 
outcomes, with the confidence intervals excluding relative 
risks greater than 50%. Given the limited number of studies 
there was not the power to evaluate MS drugs separately in 
an adequate manner. The results were driven by interferon, 
GA and natalizumab; therefore, it is not possible to gen-
eralize to other drugs such as fingolimod, azathioprine or 
rituximab. Given the diverse mechanisms by which these 
DMDs work, understanding each DMD individually is 
highly important; therefore, there is a need for studies with 
large sample sizes that present their results stratified by type 
of drug.
The biggest limitation was the number of available pub-
lished studies and the small sample sizes in these studies. 
Small sample sizes might be partially due to labels restrict-
ing the use of most MS drugs during pregnancy. There was 
only one study which used a national commercially insur-
ance population which included a large sample size (574 
DMD exposed); however, the authors do not present their 
data stratified by type of drug, and therefore, it was only 
Fig. 3  a Meta-analysis pre-term 
birth: treated MS vs untreated 
MS. b Meta-analysis pre-term 
birth: treated MS vs untreated 
MS stratified by drug
Overall  (I-squared = 46.0%, p = 0.085)
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a
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.
.
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Subtotal  (I-squared = 0.0%, p = 0.377)
0.61 (0.11, 3.29)
0.79 (0.60, 1.04)
1.54 (1.03, 2.29)
0.64 (0.33, 1.25)
0.92 (0.58, 1.46)
0.75 (0.47, 1.20)
0.94 (0.54, 1.65)
0.82 (0.57, 1.18)
0.58 (0.27, 1.25)
0.85 (0.58, 1.25)
0.79 (0.56, 1.12)
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Fig. 4  a Meta-analysis major 
congenital malformations: 
treated MS vs untreated MS. b 
Meta-analysis major congenital 
malformations: treated MS vs 
untreated MS stratified by drug
Overall  (I-squared = 26.1%, p = 0.221)
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0.55 (0.22, 1.43)
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2.83 (0.29, 27.81)
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0.55 (0.22, 1.43)
0.15 (0.01, 2.85)
0.70 (0.30, 1.60)
0.22 (0.04, 1.04)
0.77 (0.05, 12.15)
1.52 (0.27, 8.54)
0.58 (0.16, 2.12)
.1 .2 .5 1 2 5 10
b
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Table 2  Meta-analyses of 
prevalence in the different group 
studied
Prevalence takes into account weights. I2 = 0–40% might not be important, 30–60% moderate heterogene-
ity, 50–90% substantial heterogeneity, 75–100% considerable heterogeneity
a Denominator = number of pregnancies
n/N Prevalence LCI 95% UCI 95% I2% Heteroge-
neity (95% CI)
Spontaneous abortions
 Untreated MS 378/2805 10.9% 5.2% 18.3% 96 (93–97)
 All MS Drugs 275/2006 11.6% 7.4% 16.7% 88 (82–92)
Premature birth
 Untreated MS 376/2666 12.1% 7.4% 17.7% 73 (57–84)
 All MS drugs 247/2001 12.1% 9.0% 15.6% 92 (86–95)
Major congenital  malformationsa
 Untreated MS 67/1691 4.2% 2.7% 6.1% 61 (21–80)
 All MS drugs 33/1040 3.0% 1.8% 4.4% 19 (0–58)
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possible to stratify the results for interferons, natalizumab 
and GA. There were 13 studies which we had to exclude, 
because they had not included controls. This shows that 
there is a great interest in studying the safety of MS drugs 
during pregnancy; however, there is a need for studies using 
internal comparators to assess the risk comparing patients 
taking MS drugs vs patients not taking medication as well 
as studying in the same study different MS drugs and taking 
into account confounding factors.
A limitation of these meta-analyses and pregnancy stud-
ies in general is the lack of adjustment for confounding fac-
tors such as age, comorbidities, comedications, trimester of 
exposure and environment. Future studies should consider 
large databases to conduct observational studies. These 
databases have the advantage of providing large popula-
tions that increase the power and reduce the risk of reporting 
bias. In addition, by increasing the size of the population, 
it will be possible to evaluate the risk given by each drug 
in each trimester of exposure and evaluate other outcomes. 
It is likely that most of the patients were exposed to DMDs 
during the first trimester of pregnancy. However, of all the 
studies identified, there was only one study which focused 
on the exposure of natalizumab during the first trimester 
[16]. In addition, there is a need to understand the safety 
risk when exposed later in pregnancy. For example, hemato-
logical abnormalities (anemia and thrombocytopenia), were 
reported in babies exposed to natalizumab in late pregnancy 
[17].Concerning the evaluation of other outcomes, Houtch-
ens et al. [18] using an administrative claims database from 
the United States compared the pregnancy prevalence com-
plications in women with and without MS. They reported 
that women with MS when compared with women without 
MS had a higher frequency of premature labor, infections, 
cardiovascular disease, anemia/acquired coagulation disor-
ders and neurological malformations. They did not study 
if DMDs increased the risk; however, they estimated that 
only 20% of the MS patients were exposed to a DMD dur-
ing pregnancy. Future studies using large databases will be 
adequate to study the safety related to different outcomes.
Seven out of the ten studies, mentioned the type of 
major congenital malformations that were present in the 
patients taking MS drugs; however, only two presented the 
major congenital malformations in the control groups. In 
the MS patients exposed to DMDs there was no specific 
pattern seen. The most common major congenital mal-
formations were atrial septal defect (ASD) (N = 4), poly-
dactyly (N = 4) and club foot (N = 3), which are among 
the most prevalent birth defects observed in the general 
Table 3  List of major malformations reported in the exposed patients to MS drugs
a Author does not specify whether this is a major or minor malformation, does not specify what type of hernia
N Organs Number of births with anomaly Total number of 
exposed births
Study
6 Cardio-Pulmonar 1 Atrioventricular Canal 25 Weber-Schoendorfer and Schaefer et al. [24]
1 Atrial septal defect 77 Ebrahimi et al. [16]
3 Atrial septal defects 226 Thiel et al. [14]
1 Pulmonary artery stenosis 226 Thiel et al. [14]
4 Renal 1 Ureteropelvic stenosis 226 Thiel et al. [14]
1 Pyloric stenosis 136 Herbstritt et al. [13]
2 Ureteral duplication 226 Thiel et al. [14]
136 Herbstritt et al. [13]
9 Skeletal 4 Polydactyly 75 Portaccio et al. [15]
226 Thiel et al. [14]
226 Thiel et al. [14]
77 Ebrahimi et al. [16]
1 Macrodactyly 226 Thiel et al. [14]
1 dysmelia of the tibia and  fibulaa 226 Thiel et al. [14]
3 Club foot 25 Weber-Schoendorfer and Schaefer et al. [24]
54 Portaccio et al. [15]
226 Thiel et al. [14]
2 2 Down syndrome 54 Portaccio et al. [15]
12 Boskovic et al. [23]
1 1 Hernia** 77 Ebrahimi et al. [16]
1 1 “Abnormality of the X Chromosome” 12 Boskovic et al. [23]
1 1 Wolf Hirschhorn syndrome 226 Thiel et al. [14]
 Journal of Neurology
1 3
population [19]. In addition, the only studies that pre-
sented the major congenital malformations in controls 
also listed ASD. The cases of polydactyly were present 
in β-interferon and natalizumab patients and the club foot 
in patients exposed to GA and natalizumab. The biggest 
study did not list the major malformations [12]. We con-
tacted the authors and they stated that given that the study 
was performed in claims database it was not permitted to 
publish non-aggregated data.
It is important to note that not all the studies used the 
same definition for major congenital malformation. Even 
for the same type of congenital malformation, some authors 
considered it to be major and others minor. For example, 
Portaccio et al. [15] classified hip dysplasia as a major con-
genital malformation, and Thiel et al. [14] classified it as a 
minor congenital malformation. In addition, Thiel did not 
mention if dysmelia of the tibia and fibula was considered 
major or minor and Herbstritt et al. [13] considered it major. 
Classifications such as the EUROCAT and The Metropolitan 
Atlanta Congenital Defects Program (MACDP) need to be 
considered at all times when performing pregnancy studies 
[19, 20]. In addition, there is a need for standardization, and 
especially if secondary sources of data are used, algorithms 
to define pregnancy outcomes need to be carefully validated.
In addition to DMDs being recommended not to be used 
during pregnancy, for most DMDs, the European Medi-
cine Agency recommends adding contraception measures 
and time on contraception after the last dose of treatment 
(e.g., fingolimod 2 months) [21]. Therefore, evidence of 
pregnancy occurrence and its outcomes in women with MS 
exposed to these DMDs might take years to gather through 
traditional pregnancy registries. In this study, results coming 
from primary collection in MS pregnancy registries were 
similar to those from secondary use of data. Secondary use 
of data sources with broad country coverage have the poten-
tial to identify a much higher number of exposed cases in 
a more timely manner and minimizes loss to follow-up of 
pregnant women and infants.
A recently initiated IMI2 project named ConcePTION, 
which the authors are part of, will enable the use of such 
data [22]. This meta-analysis aims to provide guidance on a 
future study that will assess the safety of MS drugs during 
pregnancy. In the future study we will tackle some of the 
limitations observed in the studies we present in this meta-
analysis which include the stratification of different DMDs, 
standardization of definitions and adjustment for confound-
ing factors. In conclusion, interferons, GA or natalizumab, 
do not appear to increase the risk for spontaneous abortions, 
pre-term birth or major congenital malformations. There 
were very few patients included that were exposed with 
fingolimod, azathioprine and rituximab; therefore, these 
results cannot be generalized across drugs. Future studies 
including internal comparators are needed to enable treating 
physicians and their patients to decide on the best treatment 
options.
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